StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Xilio Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Xilio Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -34.1%. For fiscal 2025 it was -80.1%, against -918.0% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-80.1%+838.0
FY2024Dec 31, 2024-918.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-34.1%+161.9
Q1 FY2026Mar 31, 2026-75.3%+377.4
Q4 FY2025Dec 31, 202575.7%+835.2
Q3 FY2025Sep 30, 2025-85.4%+534.1
Q2 FY2025Jun 30, 2025-196.0%+394.8
Q1 FY2025Mar 31, 2025-452.7%–
Q4 FY2024Dec 31, 2024-759.5%–
Q3 FY2024Sep 30, 2024-619.5%–
Q2 FY2024Jun 30, 2024-590.8%–

More Xilio Therapeutics figures

See a number that looks wrong?